How This Works
CJC-1295 (no DAC) is a modified GHRH analog (tetrasubstituted 29-amino acid peptide) that stimulates pulsatile GH release from the pituitary. Human studies demonstrate sustained, dose-dependent increases in both GH and IGF-1 with subcutaneous administration. Ipamorelin is a pentapeptide GH secretagogue with a half-life of approximately 1.5–2.5 hours that elicits a rapid GH pulse peaking around 40 minutes post-dose. Importantly, Ipamorelin selectively increases GH without affecting ACTH, cortisol, or prolactin levels. When combined, these peptides may produce synergistic GH release by acting on complementary receptor pathways.
Potential Benefits & Side Effects
Observations from preclinical and clinical literature.
Supports sustained GH and IGF-1 elevation through pulsatile release patterns.
Ipamorelin demonstrates selective GH release without cortisol or ACTH elevation.
Once-daily dosing of CJC-1295 (no DAC) has been shown to normalize growth in animal models.
Generally well tolerated; possible transient effects may include flushing, headache, or injection-site reactions.
Some individuals report increased appetite, water retention, or tingling sensations.
Dosage Guide: http://help.datapeptides.com/en/articles/15074074-cjc1295-no-dac-ipamorelin-10mg-blend-vial-dosage-protocol
Disclaimer:
The information provided in this article is for educational and informational purposes only and is not intended as medical advice. These statements have not been evaluated by the FDA or Health Canada. Peptides and other compounds discussed are intended for research purposes only and are not approved for human consumption unless prescribed by a licensed medical professional. Always consult your healthcare provider before starting any new protocol, supplement, or treatment.